Manipulation of B-cell responses with histone deacetylase inhibitors
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Manipulation of B-cell responses with histone deacetylase inhibitors
Authors
Keywords
-
Journal
Nature Communications
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-04-27
DOI
10.1038/ncomms7838
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Quantitative Regulation of B Cell Division Destiny by Signal Strength
- (2014) M. L. Turner et al. JOURNAL OF IMMUNOLOGY
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
- (2013) P. G. Richardson et al. BLOOD
- An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors
- (2013) A. C. West et al. CANCER RESEARCH
- Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
- (2013) D J DeAngelo et al. LEUKEMIA
- HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses
- (2013) J E Bolden et al. Cell Death & Disease
- Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma
- (2013) G M Matthews et al. Cell Death & Disease
- Regulation of asymmetric cell division and polarity by Scribble is not required for humoral immunity
- (2013) Edwin D. Hawkins et al. Nature Communications
- HDAC inhibitor therapy in autoimmunity and transplantation
- (2012) Wayne W Hancock et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
- (2012) Brad H. Rovin et al. ARTHRITIS AND RHEUMATISM
- LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice
- (2012) Dapeng Wang et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy
- (2012) M. Chesi et al. BLOOD
- HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation
- (2011) Matthew J Sweet et al. IMMUNOLOGY AND CELL BIOLOGY
- Unknown
- (2011) Christopher Reilly et al. MOLECULAR MEDICINE
- Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
- (2011) Marcus Bantscheff et al. NATURE BIOTECHNOLOGY
- Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis
- (2010) Roel H Wilting et al. EMBO JOURNAL
- Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression
- (2010) T. Yamaguchi et al. GENES & DEVELOPMENT
- Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
- (2010) Michael Dickinson et al. INVESTIGATIONAL NEW DRUGS
- BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs
- (2010) E. M. Carrington et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mcl-1 Is Essential for Germinal Center Formation and B Cell Memory
- (2010) I. Vikstrom et al. SCIENCE
- Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
- (2009) Joan T. Merrill et al. ARTHRITIS AND RHEUMATISM
- Using histone deacetylase inhibitors to enhance Foxp3+ regulatory T-cell function and induce allograft tolerance
- (2009) Liqing Wang et al. IMMUNOLOGY AND CELL BIOLOGY
- Autoimmune Disease in Lyn-Deficient Mice Is Dependent on an Inflammatory Environment Established by IL-6
- (2009) E. Tsantikos et al. JOURNAL OF IMMUNOLOGY
- Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin
- (2008) A. Newbold et al. MOLECULAR CANCER THERAPEUTICS
- HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen
- (2008) N. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now